{"id":"W4416139878","doi":"10.1093/neuonc/noaf201.1670","title":"TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Agile software development; Clinical trial; Glioblastoma; Randomization; Phases of clinical research; Drug development; Disease; Clinical endpoint; Biomarker","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055742,0.0008994507,0.001750853,0.0004317288,0.0002790491,0.001234839,0.0008901042,0.001114438,0.005816055],"category_scores_gemma":[0.005630279,0.000225964,0.002334174,0.0005639559,0.0004570375,0.001308275,0.0007848248,0.003950608,0.001128714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008505948,"about_ca_system_score_gemma":0.001587072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007870961,"about_ca_topic_score_gemma":0.002727188,"domain_scores_codex":[0.9987256,0.0008177923,0.0000673246,0.0001219647,0.0001597932,0.000107615],"domain_scores_gemma":[0.9974298,0.00101044,0.0003868605,0.0001958318,0.0003340564,0.0006430484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1194338,0.004544288,0.004212287,0.003725655,0.003217847,0.0002093709,0.0002077721,0.007548975,0.00636959,0.003177991,0.1131381,0.7342144],"study_design_scores_gemma":[0.597705,0.1648469,0.02706738,0.003749511,0.004872588,0.0007997042,0.0002291604,0.01367274,0.005670317,0.01594206,0.165215,0.0002296778],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6916921,0.09198955,0.03399471,0.0630596,0.006383406,0.01542909,0.04367332,0.0043678,0.04941034],"genre_scores_gemma":[0.7892399,0.04467228,0.04679141,0.04481521,0.002337219,0.02385521,0.02929363,0.001069058,0.01792619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005816055,"threshold_uncertainty_score":0.0294795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03798152204161998,"score_gpt":0.365103677102033,"score_spread":0.327122155060413,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}